South San Francisco, Calif. — September 2, 2025 — Leads & Copy — Maze Therapeutics, Inc. (Nasdaq: MAZE) has appointed Misbah Tahir as chief financial officer (CFO), effective immediately.
Jason Coloma, Ph.D., chief executive officer of Maze, said the company is thrilled to welcome Misbah as Maze’s Chief Financial Officer and that Misbah’s proven track record in scaling biotech companies will be instrumental in driving their growth strategy.
Mr. Tahir brings more than 20 years of financial and strategic experience in the biopharmaceutical industry. He most recently served as CFO of IGM Biosciences, Inc., where he helped lead the company’s 2019 initial public offering and worked with the executive team to raise more than $1 billion across multiple equity financings and a pharma partnership.
Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients with kidney and metabolic diseases. Maze’s pipeline is led by MZE829, an oral APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease, and MZE782, an oral SLC6A19 inhibitor advancing through Phase 1 with the potential to treat both chronic kidney disease (CKD) and phenylketonuria (PKU).
Amy Bachrodt, Maze Therapeutics, abachrodt@mazetx.com
Amanda Lazaro, 1AB Media, Amanda@1ABMedia.com
Source: Maze Therapeutics
